Endogenex
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Minnesota, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
13755 1st Ave North 100, Plymouth, Minne...Phone Number
(763) 251-6820Website
www.endogenex.comRevenue
$12.3 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Endogenex
Endogenex is pioneering a treatment for type 2 diabetes that targets what research now points to as a likely cause: a damaged duodenum. The companys novel, outpatient endoscopic procedure uses non-thermal pulsed electric fields (PEF) energy to treat inflamed and dysfunctional tissue associated with type 2 diabetic duodenopathy. A specialized Endogenex catheter delivers PEF to the mucosa and sub-mucosa duodenal tissue, initiating the bodys natural process of cell regeneration. Our goal is to restore the gut to a healthier state, so we may help patients do more than manage their symptoms and potentially slow, or even stop, their disease progression. By following the science to the gut, we hope to redefine whats possible for diabetes care.Explore more
Endogenex Org Chart
Get the full picture
Sign in to uncover key details.
LH
Senior Field Clinical Specialist
ED
Field Clinical Specialist
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Endogenex your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Endogenex recently announced quarterly report
Endogenex, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Endogenex is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Endogenex launches new products
Click to see if Endogenex had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Endogenex has new funding data
Congratulate Masked Content for being promoted to Masked Content at Endogenex
Check if Endogenex has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Endogenex
Compare insights from companies similar to Endogenex, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Endogenex is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Endogenex is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Endogenex.
Endogenex financials insights
Gather financial insights about Endogenex, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series A
$34M
Series B
$18.3M
2024
Series C
$88M
2026
Series C
$50M
Endogenex Tech Stack
A closer look at the technologies used by Endogenex
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Person-Based
Person-Based
Person-Based
Endogenex News & Media
Endogenex Announces Full Enrollment of the ReCET Clinical Study
350 Patients Enrolled Across Sites in the United States and Australia, Advancing the Path to FDA Approval of a Novel Endoscopic Treatment for Type 2 Diabetes 350 Patients Enrolled Across Sites in the United States and Australia, Advancing the Path to FDA Approval of a Novel Endoscopic Treatment for Type 2 DiabetesEndogenex Pockets $50M Series C Extension for Endoscopic Diabetes Procedure
The proceeds will help Endogenex fund completion of its pivotal ReCET clinical trial and support its path to FDA approval.Endogenex Closes $50 Million Series C
MINNEAPOLIS, MN, Endogenex, a clinical-stage medical technology company, announced the closing of a $50 million extension of its Series C financing.Endogenex Closes $50 Million Series C Extension to Fund Pivotal Clinical Study and Path to FDA Approval
Arboretum Ventures leads financing, with participation from existing investors, as Endogenex advances its novel treatment targeting a damaged duodenum as a driver of type 2 diabetes Arboretum Ventures leads financing, with participation from existing investors, as Endogenex advances its novel treatment targeting a damaged duodenum as a driver of type 2 diabetes
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Endogenex
Sign Up For FreeTo access detailed company insights
Endogenex is pioneering a treatment for type 2 diabetes that targets what research now points to as a likely cause: a damaged duodenum. The companys novel, outpatient endoscopic procedure uses non-thermal pulsed electric fields (PEF) energy to treat inflamed and dysfunctional tissue associated with type 2 diabetic duodenopathy. A specialized Endoge... Read More
